Financial Wire

Geopolitics, Beijing Regulatory Changes Lift Asian Stock Markets

-- Asian stock markets tracked north on Monday, as traders weighed pending Tehran-Washington negotiations regarding the Persian Gulf, and revamped securities-industry rules issued late Friday in Beijing.

Hong Kong, Shanghai and Tokyo finished in green, as did most other regional exchanges.

In Japan, the Nikkei 225 opened higher and held ground, finishing up 0.6% as traders mulled the outlook for US and Iranian negotiations this week in Pakistan.

The benchmark Nikkei 225 rose 348.99 to 58,824.89, as gaining issues outnumbered losers 123 to 98.

Leading the upside was Renesas Electronics, up 6.4%, while Sumitomo Pharma declined 5.9%.

In Hong Kong, the Hang Seng Index opened evenly and gained in trading, closing up 0.8% on investor acceptance of securities-industry rules changes in China.

The broad gauge Hang Seng rose 200.74 to 26,361.07 as gaining issues outnumbered losers 61 to 28. The Hang Seng TECH Index gained 0.5% on the day, while the Mainland Properties Index rose 0.3%.

Leading the upside was Xinyi Solar, gaining 6.2%, while PetroChina declined 3.3%.

On the mainland, the Shanghai Composite rose 0.8% to 4,082.13.

In industry news, the China Securities Regulatory Commission (CSRC) and other authorities late Friday announced changes to regulations to strengthen market supervision and attract long-term investment.

In general, the new rules ease investment by "strategic investors," or institutional money, into Chinese public companies, particularly into the powerful, voting "A-share" class, but also tighten rules on the illegal selling of shares, and the practice of "auditor shopping" for accounting services.

On the other regional exchanges, the S. Korean KOSPI rose 0.4%; the Taiwan TWSE inclined 0.4%; the Australian ASX 200 inclined 0.1%; the Singapore Straits Times Index rose 0.1%, and the Thai Set was steady. In late trading in Mumbai, the Sensex was down 0.1%

The MSCI All Country Asia Pacific Index rose 0.3% on the day.

相关文章

Australia

Arcus Biosciences因疗效不佳而终止3期肺癌试验

Arcus Biosciences (RCUS) 周一宣布,由于独立数据监测委员会建议因疗效不佳而终止其针对转移性非小细胞肺癌的 STAR-121 III 期临床试验,该公司已停止该试验。 该公司表示,这项与吉利德科学公司 (GILD) 合作开展的临床试验,旨在评估 domvanalimab 联合 zimberelimab 和化疗与 pembrolizumab 联合化疗作为一线治疗方案的疗效。 此前,一项预先设定的疗效分析表明,该疗法不太可能达到其主要终点,因此公司决定终止该试验。 周一,Arcus Biosciences 的股价下跌了 5%。Price: $23.05, Change: $-1.20, Percent Change: -4.95%

$GILD$RCUS
Australia

Sila Realty Trust 将以 24 亿美元的价格被 Blue Owl Affiliates 私有化

Sila Realty Trust (SILA) 同意被 Blue Owl Capital (OWL) 旗下房地产部门的某些关联公司以全现金方式收购并私有化,交易金额约为 24 亿美元。 两家公司周一表示,净租赁房地产投资信托基金 Sila 的股东将获得每股 30.38 美元,较上周五的收盘价溢价 19%。 该交易尚需 Sila 股东批准,预计将于今年第二或第三季度完成。交易完成后,该公司将从纽约证券交易所退市。 Sila 首席执行官 Michael Seton 在一份声明中表示:“此次交易的完成将为我们的股东带来显著且立竿见影的收益。” 周一,Sila 股价上涨 19%。资产管理公司 Blue Owl 的股价上涨 1%。 专注于医疗设施投资的Sila公司表示,截至3月底,其投资组合包括美国137处房地产物业和3块未开发土地。其网站数据显示,该投资组合包括86栋医疗门诊大楼、25家住院康复机构以及26家外科和专科设施。 “此次交易为我们提供了一个绝佳的机会,可以收购一个规模庞大、现金流稳定且具有良好长期增长前景的投资组合,同时进一步扩大Blue Owl管理基金在该资产类别和行业的投资。鉴于医疗设施在社会和经济中发挥的关键作用,我们认为该类别和行业既具有韧性又至关重要。”Blue Owl联席总裁兼全球实物资产主管Marc Zahr表示。 今年2月,Sila公布第四季度调整后运营资金为每股0.55美元,高于去年同期的0.54美元。营收从4650万美元增至5070万美元。 Sila计划在交易完成前支付至多两次季度股息。Price: $30.44, Change: $+4.90, Percent Change: +19.19%

$OWL$SILA
Australia

嘉年华股东批准单一公司结构和重新注册

嘉年华邮轮公司(Carnival,股票代码:CCL,CUK)周一表示,其多数股东已批准将公司双重上市结构简化为单一公司,并将嘉年华集团的注册地从巴拿马迁至百慕大。 该公司表示,预计上述变更将于5月7日生效。Price: $28.69, Change: $-0.53, Percent Change: -1.81%

$CCL$CUK